Shots:
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients
During the month of June, Samsung Bioepis presented results of SB12…
Shots:
Driven by the influx of life-changing innovations and technological advances, the pharmaceutical industry is forging ahead at a momentous pace. With the impelling Pharma 4.0, automation has now been embedded in various aspects of current business practices
Delving deeply into the importance of automation, primarily focusing on AI & ML, PharmaShots unveils its eight-step…
Shots:
In the wake of International Labour Day, PharmaShots presents a detailed take on the recent layoffs in the Pharmaceutical Sector with an illustrative graphical analysis
Like any sector, the pharmaceutical industry operates on some nuance and intricate aspects that ensure smooth operations. Factors like digitalization, patent expiry, growing competition, and others put direct or…
Shots:
With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing
While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…
Shots:
Biopharma companies have kept themselves afloat in the ocean of uncertainties by overcoming the hurdles of unmet demands, procurement, and maintaining a constant supply chain. However, the previous year was difficult for biopharma companies as the segment saw multiple insolvencies.
Amidst all kinds of obstacles, many companies have sustained themselves to meet the market…
Shots:
Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions
Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Some companies accept the offered period and open doors to biological drugs or biosimilars. In…
Shots:
Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnership
To tackle such scenarios, companies are cautious enough to make backup plans beforehand…
Shots:
The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March month
Darzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugs
The report summarizes the key features of Darzalex including revenue…
Shots:
The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community
The major announcement…
Shots:
The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B
In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

